Formoterol turbuhaler as a rescue therapy was as effective and safe as salbutamol by pMDI and spacer in patients with acute severe asthma
S. Charoenratanakul, W. Boonsawat, C. Pothiratana, K. Sawanyawisuth, T. Seearamrungruang, T. Bengtsson, R. Brander, O. Selroos (Bangkok, Chiang Mai, Thailand; Lund, Sweden)
Source: Annual Congress 2002 - Asthma - Therapy and management -3
Session: Asthma - Therapy and management -3
Session type: Thematic Poster Session
Number: 436
Disease area: Airway diseases
Abstract Formoterol (F) (Oxis® Turbuhaler®), has the potential to be used as a reliever medication. We have examined its effectiveness and safety in acute severe asthma. Eighty-eight emergency room patients (24 men; mean age 44 years, range 18-67; FEV1 30-60% predicted; pulse rate >=100 beats/min for patients >50 years of age) were randomised in a double-blind, double-dummy study to receive either 18+18+18 μg of F (delivered doses) or 800+800+800 μg of salbutamol pMDI plus spacer (S) at times 0, 30 and 60 min. Mean baseline FEV1 was 1.07 L (44% predicted normal). FEV1 , ECG, S-K+ and AEs were monitored for 4 hours. Increases in FEV1 from baseline to 75 min (primary variable) were: +37% in F- and +28% in S-treated patients (p=0.18). Average and maximum FEV1 over 4 hours increased by 12% and 11% more with F than S, respectively (p<0.04; both comparisons). No treatment differences were found for heart rate and QTc. S-K+ decreased more with F than S to 3.24 and 3.49 mmol/L, respectively (p=0.002). No discontinuations due to AEs were reported. Conclusion: Oxis® Turbuhaler® 54 μg was well tolerated and as effective and safe as salbutamol 2400 μg by pMDI plus spacer in patients with acute severe asthma.
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Charoenratanakul, W. Boonsawat, C. Pothiratana, K. Sawanyawisuth, T. Seearamrungruang, T. Bengtsson, R. Brander, O. Selroos (Bangkok, Chiang Mai, Thailand; Lund, Sweden). Formoterol turbuhaler as a rescue therapy was as effective and safe as salbutamol by pMDI and spacer in patients with acute severe asthma. Eur Respir J 2002; 20: Suppl. 38, 436
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Formoterol turbuhaler is effective and safe compared with salbutamol by pMDI and spacer as reliever therapy in patients with acute severe asthma Source: Eur Respir J 2002; 20: Suppl. 38, 52s Year: 2002
Treatment of acute severe asthma with formoterol Turbuhaler provides a similar effect on patients' well-being as salbutamol by pMDI plus spacer Source: Eur Respir J 2002; 20: Suppl. 38, 47s Year: 2002
Budesonide and formoterol in a single inhaler is safe and effective in the treatment of asthma Source: Eur Respir J 2001; 18: Suppl. 33, 159s Year: 2001
Once daily ciclesonide delivered via pMDI is effective and safe for the treatment of mild-to-moderate persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 208s Year: 2006
Once-daily budesonide/formoterol via a single inhaler is effective in mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001
Budesonide/formoterol in a single inhaler is as effective and well tolerated as salbutamol in relieving acute asthma in adults and adolescents Source: Eur Respir J 2003; 22: Suppl. 45, 445s Year: 2003
Budesonide and formoterol in a single inhaler is more effective than a higher dose of inhaled corticosteroid in mild-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 159s Year: 2001
Budesonide/formoterol in a single inhaler is more effective than a higher dose of inhaled corticosteroids in patients with mild persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 387s Year: 2002
The novel budesonide HFA pMDI is clinically comparable to the conventional budesonide CFC pMDI in paediatric patients with asthma Source: Eur Respir J 2005; 26: Suppl. 49, 160s Year: 2005
Formoterol Turbuhaler as reliever medication in patients with acute asthma Source: Eur Respir J 2006; 27: 735-741 Year: 2006
Formoterol and budesonide/formoterol are both equally as fast and effective as salbutamol in relieving severe acute bronchospasm Source: Eur Respir J 2004; 24: Suppl. 48, 541s Year: 2004
Utility of inhaled corticosteroids (fluticasone/formoterol) by pressurized metered-dose inhaler for the early management of acute exacerbations of asthma Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010
Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator therapeutic response as that administered by the Rotahaler in adults with chronic obstructive pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 125s Year: 2005
Budesonide and formoterol in a single inhaler controls exacerbations more effectively than a higher dose of inhaled corticosteroids alone, in mild-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 43s Year: 2001
Bronchodilator response to salbutamol administered through metered-dose inhaler plus spacer or dry-powder inhaler in asthmatic patients Source: Eur Respir J 2001; 18: Suppl. 33, 101s Year: 2001
Adjustable maintenance treatment of asthma with budesonide and formoterol in a single inhaler Source: Eur Respir J 2002; 20: Suppl. 38, 397s Year: 2002
Improved and maintained asthma control with once-daily budesonide/formoterol single inhaler therapy in mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001
Budesonide/formoterol in a single inhaler once or twice daily provides better asthma control than inhaled fluticasone or budesonide alone in patients with moderate persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 387s Year: 2002
Efficacy and safety of the new beclomethasone dipropionate/formoterol combination vs. fluticasone propionate/salmeterol pMDIs in moderate to severe persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 205s Year: 2006
Formoterol-HFA pMDI is effective and well tolerated in children with persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 712s Year: 2006